Welcome to our dedicated page for Perrigo Co Plc SEC filings (Ticker: PRGO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Perrigo Company plc (NYSE: PRGO) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures, including current reports on Form 8-K and other key documents filed with the Securities and Exchange Commission. Perrigo is incorporated in Ireland and files its reports as a foreign private issuer with ordinary shares listed on the New York Stock Exchange under the symbol PRGO.
Through its Form 8-K filings, Perrigo reports material events such as quarterly earnings releases, strategic reviews and significant transactions. Recent 8-Ks have furnished earnings results for its Consumer Self-Care Americas and Consumer Self-Care International segments, described non-GAAP measures such as adjusted operating income, adjusted diluted earnings per share, organic net sales and constant currency net sales, and outlined the items excluded in these non-GAAP metrics, including amortization of acquired intangibles, restructuring charges, unusual litigation, impairment charges, divestiture gains or losses and infant formula remediation.
Other 8-K filings detail corporate actions such as the entry into a Master Sale and Purchase Agreement to sell Perrigo’s Dermacosmetics branded business in Northern Europe, the Netherlands and Poland, and executive leadership changes and related compensation arrangements. These filings provide insight into how the company is managing its portfolio, capital allocation and organizational structure.
On Stock Titan, users can view Perrigo’s filings as they are made available from EDGAR and use AI-powered summaries to understand the main points of lengthy documents. This includes context around earnings-related disclosures, explanations of non-GAAP reconciliations and highlights from transaction agreements and governance updates. For investors tracking PRGO, this page serves as a centralized view of Perrigo’s regulatory reporting history and ongoing disclosure practices.
Perrigo Company plc, an Ireland‑incorporated, pure‑play self‑care company, files its annual report describing a diversified over‑the‑counter health and wellness business focused on consumer self‑care in North America and Europe. The company operates through two segments: Consumer Self‑Care Americas, centered on U.S. and Canadian store brands and select branded products, and Consumer Self‑Care International, focused largely on branded self‑care across Europe and Australia.
Perrigo emphasizes innovation in categories such as upper respiratory, nutrition, digestive health, pain and sleep‑aids, oral care, healthy lifestyle, skin care, women’s health and vitamins, minerals and supplements. It highlights major efficiency initiatives, including a three‑year Supply Chain Reinvention Program that simplified its global network and is being wound down after meeting primary objectives. As of June 27, 2025, voting stock held by non‑affiliates had an aggregate market value of $3,650,573,391, and as of February 24, 2026, there were 137,649,352 ordinary shares outstanding.
The report outlines an ESG strategy around climate action, packaging, responsible sourcing, and people and communities, including a net‑zero greenhouse gas target by 2040 and broad human‑capital programs for its roughly 8,100 employees. It also provides an extensive risk factor summary spanning competition, regulation, supply chain disruption, cybersecurity, tax changes and capital structure. Perrigo notes a $21.7 million 2025 tax benefit from the U.S. One Big Beautiful Bill Act while stating that new global tax rules and U.S. reforms are not expected to materially affect its overall financial position.
Perrigo Company plc reported fourth-quarter and full-year 2025 results showing a large non-cash goodwill impairment and solid adjusted performance. A $1.3 billion goodwill impairment drove a 2025 reported net loss of $1.40 billion, or $(10.12) per share, versus a $(1.17) loss a year earlier. Adjusted net income was $381.6 million, with adjusted EPS of $2.75, up 7.0% from $2.57, helped by cost-savings programs and currency tailwinds despite softer infant formula and OTC demand. Net sales fell 2.8% to $4.25 billion, with organic net sales down 2.4% as infant formula and contract manufacturing weakened, partially offset by share gains in key brands and store brands. The company completed its Supply Chain Reinvention Program and substantially finished Project Energize, together delivering over $320 million in annual run-rate benefits, and plans fewer than $20 million of additional costs through 2026.
For 2026, Perrigo introduced an ‘All In’ outlook that includes infant formula and divestitures, guiding to net sales growth of -5.5% to -1.5% and adjusted diluted EPS of $2.00 to $2.30. It also issued a ‘CORE Perrigo’ outlook excluding infant formula and previously announced divestitures, with reported net sales growth of -3.0% to +1.0%, CORE organic net sales of -3.5% to +0.5%, and CORE adjusted EPS of $2.25 to $2.55 versus 2025 CORE adjusted EPS of $2.52. Management is launching a new two‑year operational enhancement program, targeting $80–$100 million in annualized pre‑tax savings by the end of fiscal 2027 and reducing about 7% of its workforce. Perrigo also expects to close the sale of its Dermacosmetics business for up to €327 million in the second quarter of 2026, subject to customary conditions.
Fuller & Thaler Asset Management, Inc. filed a Schedule 13G reporting beneficial ownership of 7,824,758.81 shares of Perrigo Co plc common stock, representing 5.69% of the class as of 12/31/2025.
The California-based investment adviser reports sole voting power over 7,708,573.81 shares and sole dispositive power over 7,824,758.81 shares. The shares are held for clients under investment advisory arrangements and are certified as acquired and held in the ordinary course of business without any stated intent to influence control of Perrigo.
Perrigo Company plc executive Abigail Lennox, EVP and CSO, reported equity transactions on February 6, 2026. She exercised 3,185 Restricted Stock Units, converting them into the same number of ordinary shares at $14.64 per share. To cover tax obligations, 1,660 ordinary shares were withheld at $14.64. Following these transactions, she directly holds 2,780 ordinary shares and 6,368 Restricted Stock Units, each RSU representing a contingent right to receive one ordinary share, vesting in three equal annual installments beginning February 6, 2026.
Neuberger Berman Group LLC and Neuberger Berman Investment Advisers LLC report beneficial ownership of 7,535,309 Perrigo Co PLC common shares, representing 5.5% of the class. All voting and dispositive authority over these shares is shared, with no sole power reported. The firms state the holdings are managed in various fiduciary accounts where Perrigo shares are owned economically by underlying clients. They certify the position is held in the ordinary course of business and not for the purpose of changing or influencing control of Perrigo.
BlackRock, Inc. filed an amended beneficial ownership report on Perrigo Company plc, stating that its reporting business units beneficially own 15,941,915 shares of Perrigo common stock, equal to 11.6 % of the class as of the reported date. BlackRock reports sole voting power over 15,479,279 shares and sole dispositive power over 15,941,915 shares, with no shared voting or dispositive power. The filing notes that one holder, iShares Core S&P Small-Cap ETF, has an interest in more than five percent of Perrigo’s outstanding common stock. BlackRock certifies that the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Perrigo.
Perrigo Company plc reported an insider equity award to one of its directors. On December 12, 2025, the director acquired 2,140 restricted stock units, each representing a contingent right to receive one ordinary share.
The restricted stock units are scheduled to vest on December 12, 2026. Following this grant, the director beneficially owns 41,160.148 ordinary shares on a direct basis.
Perrigo Company plc director Geoffrey Parker reported an equity award and his updated holdings in the company’s ordinary shares. On 12/12/2025, he received 2,140 Restricted Stock Units, each representing a contingent right to receive one Perrigo ordinary share, scheduled to vest on 12 December 2026.
After this award, he beneficially owns 28,912 ordinary shares directly, 25,879 ordinary shares through a revocable trust, 17,375 ordinary shares in a Roth IRA, and 2,140 Restricted Stock Units as a derivative security position.
Perrigo (PRGO): T. Rowe Price Associates, Inc. filed Amendment No. 3 to Schedule 13G reporting beneficial ownership of 16,920,302 shares of common stock, representing 12.3% of the class as of 09/30/2025.
The filer reports sole voting power over 16,856,660 shares and sole dispositive power over 16,920,302 shares, with no shared voting or dispositive power. T. Rowe Price files as an investment adviser and states the securities were acquired and are held in the ordinary course, not to change or influence control.
Within the reported holdings, T. Rowe Price Mid-Cap Value Fund has an interest in 9,190,014 shares, equal to 6.7% of the class.
Perrigo Co plc (PRGO) reported an insider transaction by director Geoffrey Parker. On 11/12/2025, Parker purchased 7,500 ordinary shares at a weighted average price of $14.18 per share, executed in multiple trades ranging from $14.16 to $14.20. The shares were acquired indirectly via a Roth IRA.
Following the transaction, Parker beneficially owned 17,375 shares indirectly (IRA), 28,912 shares directly, and 25,879 shares indirectly through a revocable trust where he and Jill Parker serve as trustees.